On January 25, 2019, Sun, Xiuli; Chi, Fuyun; Shu, Xiaohong; Ma, Xiaodong; Sun, Fangfang; Mo, Guangquan; Shangguan, Xinghe; Cai, Wei; Wang, Yao; Jiang, Feng; Wang, Yi; Sun, Guozhen published a patent.Electric Literature of 16230-24-3 The title of the patent was Pyrimidothiazole heterocyclic compound, composition, and used for treating lymphocytic leukemia. And the patent contained the following:
A pyrimidothiazole heterocyclic compound I and II having capability of treating tumor diseases by inhibiting JAK3 tyrosine kinase, Burkitt’s lymphoma, follicular lymphoma or chronic lymphocytic leukemia, and diffusing large B-cell lymphoma is provided. In compounds I and II, X is selected from the group consisting of NH or oxygen, and R1 is hydrogen, chlorine, Me, and fluorine or methoxy group;. For instance, the invention compound I (X = O; R1 = H) was prepared via substitution of 2,4-dichloro-thieno[3,2-d]pyrimidine with N-(3-hydroxyphenyl)-2-propenamide followed by substitution with 4-[3-(4-morpholinyl)propoxy]-benzenamine. The experimental process involved the reaction of N-(3-Aminophenyl)acrylamide(cas: 16230-24-3).Electric Literature of 16230-24-3
The Article related to pyrimidothiazole heterocyclic antitumor leukemia lymphoma jak inhibitor preparation, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Electric Literature of 16230-24-3
Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics